776 related articles for article (PubMed ID: 8615169)
1. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
2. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
[No Abstract] [Full Text] [Related]
3. Sinemet CR in Parkinson's disease.
Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
[TBL] [Abstract][Full Text] [Related]
4. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
Aarli JA; Gilhus NE
Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
[TBL] [Abstract][Full Text] [Related]
5. Sinemet in Parkinson's disease: efficacy with and without food.
Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
[No Abstract] [Full Text] [Related]
6. Medical treatment of Parkinson's disease.
Ahlskog JE
Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
[No Abstract] [Full Text] [Related]
7. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
[TBL] [Abstract][Full Text] [Related]
8. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
10. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG
Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861
[TBL] [Abstract][Full Text] [Related]
11. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Deleu D; Jacques M; Michotte Y; Ebinger G
Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
Lombardo L; De la Garza R
Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
Londoõ R
Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
[TBL] [Abstract][Full Text] [Related]
14. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J
Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
[TBL] [Abstract][Full Text] [Related]
15. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Rondot P; Ziegler M; Aymard N; Teinturier A
Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
[TBL] [Abstract][Full Text] [Related]
16. Case report: successful use of rectally administered levodopa-carbidopa.
Cooper SD; Ismail HA; Frank C
Can Fam Physician; 2001 Jan; 47():112-3. PubMed ID: 11212422
[No Abstract] [Full Text] [Related]
17. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
[TBL] [Abstract][Full Text] [Related]
20. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Rinne UK; Rinne JO
Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]